Synapse collects state-funded $2.4M for next-gen diaphragm pacing device

NeuRx DPS--Courtesy of Synapse

Cleveland-based Synapse Medical pulled in $2.4 million from Ohio Third Frontier, the state's tech-based economic development initiative, to help advance the next generation of the company's NeuRx diaphragm pacing system for spinal cord injury patients on a ventilator. The device, CE marked in 2007 and FDA-approved in 2008, uses four electrodes implanted under the skin to electrically stimulate the diaphragm. It has also been approved in the U.S. to treat hypoventilation associated with Lou Gehrig's disease. Synapse intends to apply the new funding to expedite its next trial. Release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.